Senate Study Bill 3136 - Introduced

SEN	ATE FILE
вч	(PROPOSED COMMITTEE
	ON JUDICIARY BILL BY
	CHAIRPERSON ZAUN)

A BILL FOR

- 1 An Act relating to the medical cannabidiol Act, and including
- 2 transition provisions.
- 3 BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA:

- 1 Section 1. Section 124E.2, subsection 2, paragraph i, Code
- 2 2020, is amended to read as follows:
- 3 i. Untreatable Severe or chronic pain.
- 4 Sec. 2. Section 124E.2, subsection 2, Code 2020, is amended
- 5 by adding the following new paragraphs:
- 6 NEW PARAGRAPH. j. Autism.
- 7 NEW PARAGRAPH. k. Post-traumatic stress disorder.
- Sec. 3. Section 124E.2, subsections 5 and 6, Code 2020, are
- 9 amended to read as follows:
- 10 5. "Health care practitioner" means an individual licensed
- 11 under chapter 148 to practice medicine and surgery or
- 12 osteopathic medicine and surgery, a physician assistant
- 13 licensed under chapter 148C, a podiatrist licensed under
- 14 chapter 149, an advanced registered nurse practitioner licensed
- 15 under chapter 152, or an advanced practice registered nurse
- 16 licensed under chapter 152E, who is a patient's primary care
- 17 provider. "Health care practitioner" shall not include a
- 18 physician assistant licensed under chapter 148C or an advanced
- 19 registered nurse practitioner licensed pursuant to chapter 152
- 20 or 152E.
- 21 6. "Medical cannabidiol" means any pharmaceutical
- 22 grade cannabinoid found in the plant Cannabis sativa L. or
- 23 Cannabis indica or any other preparation thereof that has
- 24 a tetrahydrocannabinol level of no more than three percent
- 25 and that is delivered in a form recommended by the medical
- 26 cannabidiol board, approved by the board of medicine, and
- 27 adopted by the department pursuant to rule.
- 28 Sec. 4. Section 124E.2, subsection 8, Code 2020, is amended
- 29 by striking the subsection.
- 30 Sec. 5. NEW SECTION. 124E.3A Health care practitioner
- 31 decertification.
- 32 1. The department shall adopt rules to allow a health
- 33 care practitioner who has issued a written certification to a
- 34 patient to revoke the certification.
- 35 2. A medical cannabidiol registration card issued to

S.F.

- 1 a patient or primary caregiver on the basis of a written
- 2 certification that has been revoked pursuant to subsection 1
- 3 shall not be valid after the date of revocation.
- 4 3. A patient or primary caregiver in possession of medical
- 5 cannabidiol after the revocation of a written certification
- 6 shall not be subject to a penalty under section 124E.16 for
- 7 thirty days after the revocation. Before the expiration of
- 8 thirty days after revocation, the patient or primary caregiver
- 9 shall return any unused medical cannabidiol to a medical
- 10 cannabidiol dispensary unless the patient has been recertified
- 11 pursuant to subsection 4.
- 12 4. A patient whose written certification has been
- 13 revoked pursuant to subsection 1 may receive a new written
- 14 certification pursuant to section 124E.3. If a patient
- 15 receives a new written certification within thirty days of
- 16 the revocation of the initial certification, the patient
- 17 or the patient's primary caregiver may retain any medical
- 18 cannabidiol still in the possession of the patient or the
- 19 primary caregiver. A patient shall not receive more than two
- 20 written certifications per year.
- 21 Sec. 6. Section 124E.4, subsections 1 and 5, Code 2020, are
- 22 amended to read as follows:
- 23 1. Issuance to patient.
- 24 a. Subject Except as otherwise provided in paragraph "b",
- 25 and subject to subsection 7, the department may approve the
- 26 issuance of issue a medical cannabidiol registration card by
- 27 the department of transportation to a patient who:
- 28 $\frac{\partial}{\partial x}$ (1) Is at least eighteen years of age.
- 29 b. (2) Is a permanent resident of this state.
- 30 c_{r} (3) Submits a written certification to the department
- 31 signed by the patient's health care practitioner that the
- 32 patient is suffering from a debilitating medical condition.
- 33 d_{r} (4) Submits an application to the department, on a form
- 34 created by the department, in consultation with the department
- 35 of transportation, that contains all of the following:

- 1 $\frac{(1)}{(a)}$ The patient's full name, Iowa residence address,
- 2 date of birth, and telephone number.
- 3 (2) (b) A copy of the patient's valid photo identification.
- 4 (3) (c) Full name, address, and telephone number of the
- 5 patient's health care practitioner.
- 6 (4) (d) Full name, residence address, date of birth, and
- 7 telephone number of each primary caregiver of the patient, if 8 any.
- 9 (5) (e) Any other information required by rule.
- 10 e_{r} (5) Submits a medical cannabidiol registration card
- 11 fee of one hundred dollars to the department. If the patient
- 12 attests to receiving social security disability benefits,
- 13 supplemental security insurance payments, or being enrolled in
- 14 the medical assistance program, the fee shall be twenty-five
- 15 dollars.
- 16 f. Has not been convicted of a disqualifying felony offense.
- 17 b. Subject to subsection 7, the department may issue a
- 18 medical cannabidiol registration card to a patient who provides
- 19 documentation to the department, on a form prescribed by the
- 20 department, that the patient is receiving hospice care in this
- 21 state.
- 22 5. Expiration date of card. A medical cannabidiol
- 23 registration card issued pursuant to this section shall expire
- 24 one year two years after the date of issuance and may be
- 25 renewed.
- Sec. 7. Section 124E.4, subsection 2, unnumbered paragraph
- 27 1, Code 2020, is amended to read as follows:
- 28 A medical cannabidiol registration card issued to a patient
- 29 by the department of transportation pursuant to subsection 1
- 30 shall contain, at a minimum, all of the following:
- 31 Sec. 8. Section 124E.4, subsection 3, unnumbered paragraph
- 32 1, Code 2020, is amended to read as follows:
- 33 For a patient in a primary caregiver's care, subject to
- 34 subsection 7, the department may approve the issuance of issue
- 35 a medical cannabidiol registration card by the department of

- 1 transportation to the primary caregiver who:
- Sec. 9. Section 124E.4, subsection 3, paragraph b,
- 3 unnumbered paragraph 1, Code 2020, is amended to read as
- 4 follows:
- 5 Submits an application to the department, on a form created
- 6 by the department, in consultation with the department of
- 7 transportation, that contains all of the following:
- 8 Sec. 10. Section 124E.4, subsection 3, paragraph c, Code
- 9 2020, is amended by striking the paragraph.
- 10 Sec. 11. Section 124E.4, Code 2020, is amended by adding the
- 11 following new subsection:
- 12 NEW SUBSECTION. 3A. Issuance to an institution. The
- 13 department shall adopt rules for the issuance of a caregiver
- 14 registration card to an institution, including but not limited
- 15 to a school, university, nursing home, long-term care facility,
- 16 correctional facility, or jail, allowing employees of the
- 17 institution to administer medical cannabidiol to patients in
- 18 the care of the institution.
- 19 Sec. 12. Section 124E.4, subsection 4, unnumbered paragraph
- 20 1, Code 2020, is amended to read as follows:
- 21 A medical cannabidiol registration card issued by the
- 22 department of transportation to a primary caregiver pursuant to
- 23 subsection 3 shall contain, at a minimum, all of the following:
- Sec. 13. Section 124E.4, subsection 6, Code 2020, is amended
- 25 by striking the subsection.
- Sec. 14. Section 124E.5, subsection 2, Code 2020, is amended
- 27 to read as follows:
- 28 2. The medical cannabidiol board shall convene at least
- 29 twice but no more than four times per year.
- 30 Sec. 15. Section 124E.5, subsection 3, paragraph b, Code
- 31 2020, is amended to read as follows:
- 32 b. Making recommendations relating to the removal or
- 33 addition of debilitating medical conditions to the list of
- 34 allowable debilitating medical conditions for which the medical
- 35 use of cannabidiol under this chapter would be medically

- 1 beneficial. The department shall adopt rules to modify the
- 2 list of allowable debilitating medical conditions consistent
- 3 with recommendations of the board.
- 4 Sec. 16. Section 124E.5, subsection 4, Code 2020, is amended
- 5 to read as follows:
- 6 4. Recommendations made by the medical cannabidiol board
- 7 pursuant to subsection 3, paragraphs "b" and "e", shall be made
- 8 to the board of medicine department for consideration, and if
- 9 approved, shall be adopted by the board of medicine department
- 10 by rule.
- 11 Sec. 17. Section 124E.6, subsection 4, Code 2020, is amended
- 12 to read as follows:
- 13 4. The department shall require each medical cannabidiol
- 14 manufacturer to contract with the state hygienic laboratory at
- 15 the university of Iowa in Iowa City or an independent medical
- 16 cannabidiol testing laboratory to perform spot-check testing
- 17 of the medical cannabidiol produced by the manufacturer as
- 18 provided in section 124E.7. The department shall require that
- 19 the laboratory report testing results to the manufacturer
- 20 and the department in a manner determined by the department
- 21 pursuant to rule.
- Sec. 18. Section 124E.6, Code 2020, is amended by adding the
- 23 following new subsection:
- 24 NEW SUBSECTION. 6. A medical cannabidiol manufacturer
- 25 shall pay a renewal fee of two thousand dollars per year to the
- 26 department to renew a medical cannabidiol manufacturer license
- 27 in addition to any other requirement imposed by the department
- 28 by rule.
- 29 Sec. 19. Section 124E.7, subsection 1, Code 2020, is amended
- 30 to read as follows:
- 31 l. A medical cannabidiol manufacturer shall contract with
- 32 the state hygienic laboratory at the university of Iowa in Iowa
- 33 City or an independent medical cannabidiol testing laboratory
- 34 to perform spot-check testing of the medical cannabidiol
- 35 manufactured by the medical cannabidiol manufacturer as to

- 1 content, contamination, and consistency. The cost of all
- 2 laboratory testing shall be paid by the medical cannabidiol
- 3 manufacturer. The state hygienic laboratory shall not charge
- 4 a medical cannabidiol manufacturer more than fifty thousand
- 5 dollars per year to perform spot-check testing.
- 6 Sec. 20. NEW SECTION. 124E.7A Medical cannabidiol testing
- 7 laboratory review committee.
- 8 1. The department shall establish a committee to review
- 9 product matrices, testing protocols, and testing procedures
- 10 used by the state hygienic laboratory at the university of Iowa
- 11 in Iowa City and any independent medical cannabidiol testing
- 12 laboratory operating in this state not later than September 1.
- a. The committee shall consist of the following members,
- 14 selected by the department:
- 15 (1) Three members representing independent medical
- 16 cannabidiol testing laboratories.
- 17 (2) Two members who shall be professors at regents
- 18 institutions with relevant education and experience, as
- 19 determined by rule of the department, who are not associated
- 20 with the state hygienic laboratory at the university of Iowa
- 21 in Iowa City or any independent medical cannabidiol testing
- 22 laboratory.
- 23 b. Members shall serve for a period of time as determined by
- 24 rules of the department.
- 25 3. Prior to implementing any new product matrix, testing
- 26 protocol, or testing procedure, the state hygienic laboratory
- 27 at the university of Iowa in Iowa City and any independent
- 28 medical cannabidiol testing laboratory operating in this
- 29 state shall submit the new product matrix, testing protocol,
- 30 or testing procedure to the committee. The committee shall
- 31 approve or disapprove of the product matrix, testing protocol,
- 32 or testing procedure by a simple majority vote. The state
- 33 hygienic laboratory at the university of Iowa in Iowa City
- 34 and any independent medical cannabidiol testing laboratory
- 35 operating in this state shall not use a new product matrix,

- 1 testing protocol, or testing procedure until it has been
- 2 approved by the committee, and shall not use a new product
- 3 matrix, testing protocol, or testing procedure that has been
- 4 disapproved by the committee. Product matrices, testing
- 5 protocols, and testing procedures in use prior to July 1, 2020,
- 6 shall not be subject to approval by the committee except as
- 7 provided in subsection 4.
- 8 4. A medical cannabidiol manufacturer of a product that has
- 9 failed a test administered by the state hygienic laboratory
- 10 at the university of Iowa in Iowa City or an independent
- 11 medical cannabidiol testing laboratory operating in this state
- 12 may dispute the result and request that the committee review
- 13 a product matrix, testing protocol, or testing procedure
- 14 used in testing the product. The committee shall approve or
- 15 disapprove of the result, and in the case of disapproval, shall
- 16 explain the reason for disapproval. A medical cannabidiol
- 17 manufacturer of a product tested using a product matrix,
- 18 testing protocol, or testing procedure disapproved of by the
- 19 committee may request that the product be tested again without
- 20 the disapproved product matrix, testing protocol, or testing
- 21 procedure.
- 22 5. The department shall adopt rules to administer this
- 23 section.
- Sec. 21. Section 124E.8, Code 2020, is amended by adding the
- 25 following new subsection:
- 26 NEW SUBSECTION. 5. A medical cannabidiol dispensary shall
- 27 pay an annual renewal fee of two thousand dollars to the
- 28 department to renew a medical cannabidiol dispensary license
- 29 in addition to any other requirement imposed by the department
- 30 by rule.
- 31 Sec. 22. Section 124E.9, Code 2020, is amended by adding the
- 32 following new subsections:
- 33 NEW SUBSECTION. 13. A medical cannabidiol dispensary
- 34 may employ a pharmacist or pharmacy technician licensed or
- 35 registered pursuant to chapter 155A.

```
S.F.
```

- 1 NEW SUBSECTION. 14. A medical cannabidiol dispensary shall
- 2 not dispense more than a combined total of twenty-five grams
- 3 of tetrahydrocannabinol to a patient and the patient's primary
- 4 caregiver in a ninety-day period.
- 5 Sec. 23. Section 124E.11, subsection 1, paragraph b,
- 6 subparagraph (1), subparagraph divisions (a) and (c), Code
- 7 2020, are amended to read as follows:
- 8 (a) To authorized employees or agents of the department and
- 9 the department of transportation as necessary to perform the
- 10 duties of the department and the department of transportation
- 11 pursuant to this chapter.
- (c) To authorized employees of a medical cannabidiol
- 13 dispensary, but only for the purpose purposes of verifying
- 14 that a person is lawfully in possession of a medical
- 15 cannabidiol registration card issued pursuant to this chapter
- 16 and that a patient or primary caregiver has not purchased
- 17 tetrahydrocannabidiol in excess of the amount authorized by
- 18 this chapter.
- 19 Sec. 24. Section 124E.11, subsection 1, paragraph b,
- 20 subparagraph (1), Code 2020, is amended by adding the following
- 21 new subparagraph division:
- 22 NEW SUBPARAGRAPH DIVISION. (e) To a health care
- 23 practitioner, but only for the purpose of monitoring the
- 24 amount of medical cannabidiol purchased by the health care
- 25 practitioner's patient or the primary caregiver of a patient.
- Sec. 25. Section 124E.11, subsection 2, paragraph c, Code
- 27 2020, is amended to read as follows:
- 28 c. Establish the form and quantity of medical cannabidiol
- 29 allowed to be dispensed to a patient or primary caregiver
- 30 pursuant to this chapter as appropriate to serve the medical
- 31 needs of patients with debilitating medical conditions, subject
- 32 to recommendation by the medical cannabidiol board and approval
- 33 by the board of medicine department.
- 34 Sec. 26. Section 124E.12, subsections 6 and 7, Code 2020,
- 35 are amended to read as follows:

- 1 6. The department, the department of transportation,
- 2 and any health care practitioner, including any authorized
- 3 agent or employee thereof, are not subject to any civil
- 4 or disciplinary penalties by the board of medicine or any
- 5 business, occupational, or professional licensing board or
- 6 entity, solely for activities conducted relating to a patient's
- 7 possession or use of medical cannabidiol as authorized under
- 8 this chapter. Nothing in this section affects a professional
- 9 licensing board from taking action in response to violations of
- 10 any other section of law.
- 11 7. Notwithstanding any law to the contrary, the department,
- 12 the department of transportation, the governor, or any employee
- 13 of any state agency shall not be held civilly or criminally
- 14 liable for any injury, loss of property, personal injury, or
- 15 death caused by any act or omission while acting within the
- 16 scope of office or employment as authorized under this chapter.
- 17 Sec. 27. <u>NEW SECTION</u>. **124E.20** Observational effectiveness 18 study.
- 19 The department shall, upon receipt of funding, conduct
- 20 an observational effectiveness study in cooperation with
- 21 patients and health care practitioners and pursuant to rules
- 22 of the department in order to study the effectiveness of
- 23 medical cannabidiol in the treatment of debilitating medical
- 24 conditions.
- 25 Sec. 28. PROTECTION OF FEDERAL FUNDING. The department
- 26 of public health shall request guarantees from the agencies
- 27 of the federal government providing funding to educational
- 28 and long-term care facilities that facilities with policies
- 29 allowing patients to possess medical cannabidiol on the grounds
- 30 of the facilities consistent with chapter 124E or allowing
- 31 facility staff to administer medical cannabidiol to a patient
- 32 shall not lose eligibility for any federal funding due to such
- 33 policies.
- 34 Sec. 29. TRANSITION PROVISIONS. A medical cannabidiol
- 35 registration card issued by the department of transportation

1 prior to July 1, 2020, remains effective and continues in

- 2 effect as issued for the twelve-month period following its
- 3 issuance.
- 4 EXPLANATION
- 5 The inclusion of this explanation does not constitute agreement with 6 the explanation's substance by the members of the general assembly.
- 7 This bill relates to the medical cannabidiol Act.
- 8 The bill adds autism and post-traumatic stress disorder
- 9 to the list of debilitating medical conditions for which a
- 10 written certification for a medical cannabidiol registration
- 11 card may be issued. The bill replaces "untreatable pain" with
- 12 "severe or chronic pain" on the list of debilitating medical
- 13 conditions. The bill adds licensed physician assistants,
- 14 podiatrists, advanced registered nurse practitioners, and
- 15 advanced practice registered nurses to the list of health care
- 16 practitioners that may issue written certifications for a
- 17 medical cannabidiol registration card.
- 18 The bill removes the 3 percent tetrahydrocannabinol (THC)
- 19 limit from the definition of medical cannabidiol. The bill
- 20 instead prohibits a patient or a primary caregiver from
- 21 purchasing more than 25 grams of THC in a 90-day period. The
- 22 bill allows medical cannabidiol dispensaries to access the
- 23 registry of medical cannabidiol patients to verify that a
- 24 patient or primary caregiver has not purchased more than 25
- 25 grams of THC in a 90-day period. The bill also allows a health
- 26 care practitioner to access the registry of medical cannabidiol
- 27 patients in order to monitor the amount of medical cannabidiol
- 28 purchased by the health care practitioners's patient or the
- 29 primary caregiver of a patient.
- 30 The bill removes the board of medicine from the process
- 31 of amending the acceptable form and quantity of medical
- 32 cannabidiol.
- The bill directs the department of public health to adopt
- 34 rules allowing a health care practitioner who has issued a
- 35 written certification for a medical cannabidiol registration

- 1 card to a patient to revoke that certification. A medical
- 2 cannabidiol registration card issued on the basis of a written
- 3 certification shall no longer be valid. A patient or primary
- 4 caregiver with a revoked written certification has 30 days
- 5 to dispose of medical cannabidiol still in the possession of
- 6 the patient or primary caregiver or to receive another written
- 7 certification. A patient or primary caregiver shall not
- 8 receive more than two written certifications per year.
- 9 The bill removes provisions preventing a patient or a
- 10 primary caregiver from receiving a medical cannabidiol
- 11 registration card if the patient or primary caregiver has been
- 12 convicted of a disqualifying felony.
- 13 The bill directs the department of public health to
- 14 adopt rules for issuance of a caregiver medical cannabidiol
- 15 registration card to an institution, including but not limited
- 16 to a school, university, nursing home, long-term care facility,
- 17 correctional facility, or jail, to allow employees of the
- 18 institution to administer medical cannabidiol to patients
- 19 in the care of the institution. The bill also permits the
- 20 department of public health to issue a medical cannabidiol
- 21 registration card to a patient receiving hospice care in this
- 22 state without first receiving a written certification from a
- 23 health care practitioner.
- 24 The bill changes the expiration date of medical cannabidiol
- 25 registration cards from one year after the date of issuance to
- 26 two years after the date of issuance.
- 27 The bill removes the department of transportation from the
- 28 process of applying for and receiving a medical cannabidiol
- 29 registration card and requires the department of public health
- 30 to issue medical cannabidiol registration cards and makes
- 31 conforming Code changes. A medical cannabidiol registration
- 32 card previously issued by the department of transportation
- 33 prior to July 1, 2020, remains effective and continues in
- 34 effect for the 12-month period following its issuance.
- 35 The bill allows the medical cannabidiol board to meet more

1 than four times per year.

2 The bill requires the department of public health to

3 adopt rules to modify the list of debilitating medical

4 conditions for which a certification for a medical cannabidiol

5 registration card may be issued when the medical cannabidiol

6 board recommends such a change. The bill removes the board

7 of medicine from the process of adding debilitating medical

8 conditions to the list of debilitating conditions for which a

9 written certification for a medical cannabidiol registration

10 card may be issued.

11 The bill makes changes with respect to medical cannabidiol

12 manufacturers, medical cannabidiol dispensaries, and medical

13 cannabidiol product testing. A medical cannabidiol testing

14 laboratory must report testing results to the department of

15 public health in addition to the manufacturer of the product

16 being tested. The bill provides that an annual renewal fee

17 for a medical cannabidiol manufacturer license or medical

18 cannabidiol dispensary license shall be \$2,000. The state

19 hygienic laboratory at the university of Iowa in Iowa City

20 shall not charge a medical cannabidiol manufacturer more

21 than \$50,000 per year for the testing of medical cannabidiol

22 products.

23 The bill requires the department of public health to

24 establish a committee to review product matrices, testing

25 protocols, and testing procedures used by medical cannabidiol

26 testing laboratories. The committee shall consist of five

27 members, selected by the department of public health, with

28 three members representing independent medical cannabidiol

29 testing laboratories and two members who are professors at

30 regents institutions with relevant education and experience and

31 no association with any medical cannabidiol testing laboratory.

32 Prior to implementing any new product matrix, testing protocol,

33 or testing procedure, a medical cannabidiol testing laboratory

34 must submit the product matrix, protocol, or procedure to

35 the committee for approval. A medical cannabidiol testing

- 1 laboratory shall not use a new product matrix, protocol, or
- 2 procedure that has not been approved by the committee or has
- 3 been disapproved. Product matrices, protocols, and procedures
- 4 in use prior to July 1, 2020, are not subject to review,
- 5 except that a medical cannabidiol manufacturer of a product
- 6 that has failed a test administered by a medical cannabidiol
- 7 testing laboratory may contest the results of the test with the
- 8 committee, who shall approve or disapprove the results of the
- 9 test. A manufacturer of a product that failed a test that was
- 10 disapproved by the committee may request that the product be
- 11 tested again without the disapproved product matrix, testing
- 12 protocol, or testing procedure by the committee.
- 13 The bill requires the department of public health to conduct
- 14 a study on the efficacy of medical cannabidiol in treating
- 15 patients with debilitating medical conditions upon receipt
- 16 of funding. The bill also requires the department of public
- 17 health to request guarantees from agencies of the federal
- 18 government providing funding to educational and long-term care
- 19 facilities in the state that such facilities shall not lose
- 20 such funding for allowing patients to possess and use medical
- 21 cannabidiol on the grounds of the facilities.